A11100P

DMT-dA(bz) Pharmadite^®

• Synonym(s): Adenosine, N-benzoyl-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxy-, 3′-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite], Adenosine, N-benzoyl-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxy-, 3′-[2-cyanoethyl bis(1-methylethyl)phosphoramidite], DMT-dA(bz) Phosphoramidite, N-benzoyl-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxyadenosine, 3′-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite], N6-Benzoyl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyadenosine-3′-O-[O-(2-cyanoethyl)-N,N′-diisopropylphosphoramidite]
• Empirical Formula (Hill Notation): C₄₇H₅₂N₇O₇P
• CAS Number: 98796-53-3
• Molecular Weight: 857.93
• MDL number: MFCD00036314
• UNSPSC Code: 41116107
• PubChem Substance ID: 329770659
• NACRES: NA.51

Properties

• biological source: non-animal source (no BSE/TSE risk)
• Quality Level: 300
• type: for DNA synthesis
• product line: Proligo Reagents
• assay: ≥99.5% (reversed phase HPLC); >99.5% (³¹P-NMR)
• form: powder or granules
• technique(s): oligo synthesis: suitable
• impurities: >= 170ppm, none detected (S/N <2.5); ≤0.1% P(III) 100-169ppm (³¹P-NMR); ≤0.1% single unspecified Imprity (reversed phase HPLC); ≤0.3% dA2 (reversed phase HPLC, DMT-dA(bz) cyanoethyl-H-posphonate); ≤0.3% dA3 (reversed phase HPLC, DMT-dA(bz) phosphoramidate); ≤0.30 wt. % water content (Karl Fischer); ≤0.5% P(V) -25-99ppm (³¹P-NMR); ≤3.0 wt. % residual solvent content
• color: white to off-white
• solubility: soluble, clear
• suitability: conforms to structure for H-NMR; conforms to structure for LC-MS
• nucleoside profile: base: deoxyadenosine; base protecting group: benzoyl; 2' protecting group: none; 5' protecting group: DMT; deprotection: standard
• storage temp.: 2-8°C
• SMILES string: COc1ccc(cc1)C(OC[C@H]2O[C@H](C[C@@H]2OP(OCCC#N)N(C(C)C)C(C)C)n3cnc4c(NC(=O)c5ccccc5)ncnc34)(c6ccccc6)c7ccc(OC)cc7
• InChI: 1S/C47H52N7O7P/c1-32(2)54(33(3)4)62(59-27-13-26-48)61-40-28-42(53-31-51-43-44(49-30-50-45(43)53)52-46(55)34-14-9-7-10-15-34)60-41(40)29-58-47(35-16-11-8-12-17-35,36-18-22-38(56-5)23-19-36)37-20-24-39(57-6)25-21-37/h7-12,14-25,30-33,40-42H,13,27-29H2,1-6H3,(H,49,50,52,55)/t40-,41+,42+,62?/m0/s1
• InChI key: GGDNKEQZFSTIMJ-AKWFTNRHSA-N

Description

General description

DMT-dA(bz) Pharmadite^® is a Pharmadite^® product line that represents a new class of standard protected DNA phosphoramidites that are designed with highly controlled impurity profiles and exceptional overall purity. Pharmadite phosphoramidites are characterized by their exceptional purity and well-defined impurity profile. In particular, they are essentially free from contaminants that interfere in coupling reactions, such as other nucleosidic or non-nucleosidic phosphoramidites (P(III)-contaminants). All remaining impurities in Pharmadite phosphopramidites, if present, are identified, characterized, and quantified. The impact of any such defined impurities on the synthesis of oligonucleotides is well understood and has been shown to be insignificant.

Application

Pharmadite products fulfill all requirements of starting materials for themanufacture of active pharmaceutical ingredients as defined in the EMEA "Note for guidance on the chemistry of the new active substance," making them suitable building blocks for oligonucleotide drugs.

Other Notes

Pharmadite phosphoramidites are manufactured in scales of up to multi-hundred kilos, under certified ISO 9001 quality systems.

Legal Information

Pharmadite is a registered trademark of Merck KGaA, Darmstadt, Germany

Safety Information

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable